
Publication
Calming the storm after the SVB collapse: Prudential policy the key to stability
The collapse of Silicon Valley Bank, Signature Bank and Silvergate Bank in the last week has caused turmoil in global financial market.
We use cookies and other similar technology to collect data about you to allow us to deliver our online services, measure our website audience and improve your browsing experience. Full details on the cookies we use are set out in our Cookies policy. Please click OK to signify your consent to our use of cookies.
You can withdraw your consent by clicking “manage cookies” and following the instructions shown.
Global | Publication | March 2017
Health Canada recently released for consultation the Draft Guidance Document – Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs. Stakeholders may provide comments on the draft guidance document by email to Policy_Bureau_Enquiries@hc-sc.gc.ca. The consultation period is open until April 18, 2017.
The draft guidance document outlines the conditions and procedures by which Health Canada administratively processes a change in manufacturer name and/or product name as a result of business circumstances (such as licensing arrangements or mergers/buyouts), when there are no deviations to the product.
One finalized, this guidance document will replace Health Canada’s policy Change in Manufacturer’s / Product Name Policy, which currently governs the administrative processing of drug submissions and applications.
The draft guidance document addresses current policy gaps that have been identified and provides clarity to industry on the requirements under this administrative pathway.
Generally, the types of applications that will be eligible for administrative processing include:
This draft guidance document provides additional information about the roles and responsibilities of manufacturers, licensors and licensees, as well as the types documentation and attestations required upon submission.
The draft also sets out some expectations on labelling considerations, including a six-month phased-in period to replace original product labels with new product labels for manufacturers transitioning their products under new business arrangements.
Publication
The collapse of Silicon Valley Bank, Signature Bank and Silvergate Bank in the last week has caused turmoil in global financial market.
Publication
The European Union’s Foreign Subsidies Regulation (the FSR) entered into force on 12 January 2023 and creates a new regime aimed at combating distortions of competition on the EU internal market caused by foreign subsidies. It imposes mandatory notification and approval requirements for acquisitions of significant EU businesses and large EU public tenders, and gives the European Commission (EC) extensive powers to launch ex officio investigations. The notification requirements go live on 12 October 2023.
Subscribe and stay up to date with the latest legal news, information and events...
© Norton Rose Fulbright LLP 2023